1. Home
  2. MTZ vs GMAB Comparison

MTZ vs GMAB Comparison

Compare MTZ & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MasTec Inc.

MTZ

MasTec Inc.

HOLD

Current Price

$290.21

Market Cap

22.9B

Sector

Industrials

ML Signal

HOLD

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

HOLD

Current Price

$26.10

Market Cap

19.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTZ
GMAB
Founded
1929
1999
Country
United States
Denmark
Employees
36000
N/A
Industry
Water Sewer Pipeline Comm & Power Line Construction
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9B
19.1B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
MTZ
GMAB
Price
$290.21
$26.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
19
7
Target Price
$280.44
$40.93
AVG Volume (30 Days)
884.1K
1.7M
Earning Date
05-28-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
146.12
N/A
EPS
5.07
N/A
Revenue
$14,299,171,000.00
N/A
Revenue This Year
$14.40
$17.80
Revenue Next Year
$9.38
$14.86
P/E Ratio
$58.52
$1.90
Revenue Growth
16.22
N/A
52 Week Low
$99.70
$17.24
52 Week High
$310.36
$35.43

Technical Indicators

Market Signals
Indicator
MTZ
GMAB
Relative Strength Index (RSI) 54.86 29.38
Support Level $162.35 $20.83
Resistance Level $310.36 $33.75
Average True Range (ATR) 14.32 0.64
MACD -1.70 -0.13
Stochastic Oscillator 52.39 0.53

Price Performance

Historical Comparison
MTZ
GMAB

About MTZ MasTec Inc.

MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. Its primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; pipeline infrastructure; power delivery; and other.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: